Pentazocine

Pentazocine

DEA Class; Rx

Common Brand Names; Talwin

  • Mixed Opiate Agonist-Antagonist

Synthetic opiate agonist-antagonist analgesic
One-sixth to one-third as potent as morphine
Less incidence of adverse reactions than with morphine and other opiates

Indicated for the treatment of moderate pain to severe pain.

For preanesthesia medication, as well as adjunctive use in general anesthesia induction and general anesthesia maintenance.

seizures 
increased intracranial pressure 
toxic epidermal necrolysis 
angioedema 
Stevens-Johnson syndrome
erythema multiforme 
anaphylactic shock 
apnea 
neonatal opioid withdrawal syndrome 
serotonin syndrome 
SIADH 

Pentazocine has been detected in human milk. Consider the developmental and health benefits of breast-feeding along with the mother’s clinical need for pentazocine and any potential adverse effects on the breast-fed infant from pentazocine or the underlying maternal condition.

Adults

360 mg/day IV/IM/SQ, not to exceed 30 mg/dose IV or 60 mg/dose IM/SQ.

Geriatric

360 mg/day IV/IM/SQ, not to exceed 30 mg/dose IV or 60 mg/dose IM/SQ.

Adolescents

17 years: 360 mg/day IV/IM/SQ, not to exceed 30 mg/dose IV or 60 mg/dose IM/SQ.
< 17 years: 0.5 mg/kg IM (up to 30 mg) x1 dose.

Children

0.5 mg/kg IM (up to 30 mg) x1 dose.

Infants

Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Pentazocine

Talwin Intramuscular Inj Sol: 1mL, 30mg
Talwin Intravenous Inj Sol: 1mL, 30mg
Talwin Subcutaneous Inj Sol: 1mL, 30mg

DrugsAce
Logo